Royalty Pharma Performance dei guadagni passati

Il passato criteri di controllo 3/6

Gli utili di Royalty Pharma sono diminuiti a un tasso medio annuo di -29%, mentre il settore Pharmaceuticals ha visto gli utili crescere a un tasso medio annuo di 1.2%. I ricavi sono cresciuti crescere a un tasso medio annuo di 3.8%. Il ritorno sul capitale proprio di Royalty Pharma è 16.7% e ha margini netti di 50.5%.

Informazioni chiave

-29.0%

Tasso di crescita degli utili

-31.8%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	6.0%
Tasso di crescita dei ricavi	3.8%
Rendimento del capitale proprio	16.7%
Margine netto	50.5%
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)

Nov 13

Recent updates

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 12

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

May 11

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Apr 28

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Apr 25

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Apr 04

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Feb 22

Royalty Pharma: Solid Operational Performance

Feb 19

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Jan 31

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Jan 22

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Dec 26

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

May 12

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Apr 20

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Jan 16

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Oct 12

Ripartizione dei ricavi e delle spese

Come Royalty Pharma guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGS:RPRX Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	2,266	1,145	228	2
30 Jun 24	2,238	673	229	52
31 Mar 24	2,239	799	222	52
31 Dec 23	2,355	1,135	250	52
30 Sep 23	2,324	184	264	102
30 Jun 23	2,361	255	257	77
31 Mar 23	2,359	332	261	77
31 Dec 22	2,237	43	227	177
30 Sep 22	2,247	507	200	230
30 Jun 22	2,259	466	198	295
31 Mar 22	2,278	602	191	298
31 Dec 21	2,289	620	183	200
30 Sep 21	2,286	783	187	104
30 Jun 21	2,239	972	189	19
31 Mar 21	2,195	493	187	21
31 Dec 20	2,122	495	182	26
30 Sep 20	2,008	1,745	155	34
30 Jun 20	1,934	1,863	130	52
31 Mar 20	1,880	2,052	117	68
31 Dec 19	1,814	2,349	103	83
31 Dec 18	1,795	1,378	62	393
31 Dec 17	1,598	1,210	106	118

Guadagni di qualità: RPRX ha un grande una tantum guadagno di $348.8M che ha avuto un impatto sui suoi ultimi 12 mesi di risultati finanziari pari a 30th September, 2024.

Margine di profitto in crescita: Gli attuali margini di profitto netti di RPRX (50.5%) RPRX sono più alti rispetto allo scorso anno (7.9%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di RPRX sono diminuiti del 29% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di RPRX nell'ultimo anno ( 521% ) supera la media quinquennale ( -29% all'anno).

Guadagni vs Settore: La crescita degli utili RPRX nell'ultimo anno ( 521% ) ha superato la percentuale del settore Pharmaceuticals 54.6%.

Royalty Pharma Performance dei guadagni passati

Il passato criteri di controllo 3/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)

Third quarter 2024 earnings released: EPS: US$0.92 (vs US$0.16 in 3Q 2023)

Royalty Pharma plc to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Royalty Pharma plc to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings released: EPS: US$0.011 (vs US$0.77 in 1Q 2023)

Recent updates

Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)

Consensus EPS estimates fall by 20%

Royalty Pharma: Massive Opportunity Ahead

New minor risk - Earnings quality

Upcoming dividend of US$0.21 per share

Third quarter 2024 earnings released: EPS: US$0.92 (vs US$0.16 in 3Q 2023)

Price target decreased by 7.7% to US$41.43

Royalty Pharma plc to Report Q3, 2024 Results on Nov 06, 2024

Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21

Second quarter dividend of US$0.21 announced

Royalty Pharma Declares Fourth Quarter 2024 Dividend, Payable on December 10, 2024

Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)

Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating

Consensus EPS estimates fall by 33%

Royalty Pharma: Busy Putting Capital To Work

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Upcoming dividend of US$0.21 per share

Royalty Pharma plc Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21

First quarter dividend of US$0.21 announced

Royalty Pharma plc to Report Q2, 2024 Results on Aug 08, 2024

Royalty Pharma plc Declares Dividend for the Third Quarter of 2024, Payable on September 13, 2024

Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director

Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director

Consensus EPS estimates fall by 10%

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

First quarter 2024 earnings released: EPS: US$0.011 (vs US$0.77 in 1Q 2023)

Upcoming dividend of US$0.21 per share

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Royalty Pharma plc, Annual General Meeting, Jun 06, 2024

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Fourth quarter dividend of US$0.21 announced

Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024

Royalty Pharma plc to Report Q1, 2024 Results on May 09, 2024

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Consensus EPS estimates increase by 79%

Royalty Pharma: Solid Operational Performance

Full year 2023 earnings released: EPS: US$2.54 (vs US$0.098 in FY 2022)

Upcoming dividend of US$0.21 per share at 2.9% yield

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Royalty Pharma plc to Report Q4, 2023 Results on Feb 15, 2024

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024

Consensus EPS estimates increase by 68%

Director notifies of intention to sell stock

Director recently sold US$7.1m worth of stock

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Director recently sold US$19m worth of stock

Director notifies of intention to sell stock

Consensus EPS estimates increase by 94%

Third quarter 2023 earnings released: EPS: US$0.16 (vs US$0.33 in 3Q 2022)

Upcoming dividend of US$0.20 per share at 2.9% yield

Consensus EPS estimates increase by 55%

Consensus EPS estimates increase by 15%

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Upcoming dividend of US$0.20 per share at 2.6% yield

Second quarter 2023 earnings released: EPS: US$0.51 (vs US$0.70 in 2Q 2022)

Insufficient new directors

Royalty Pharma plc Declares Dividend on Class A Ordinary Shares for the Third Quarter of 2023, Payable on September 15, 2023

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Founder recently bought US$3.8m worth of stock

Royalty Pharma plc to Report Q2, 2023 Results on Aug 08, 2023

Insider recently sold US$6.5m worth of stock